Posts by Tanuja Chitnis, MD
-
Fingolimod is Superior to Interferon Beta-1a for Relapsing MS in Children 10 and Older
A randomized, active-comparator, double-blind, multinational phase 3 trial has established the efficacy and safety of fingolimod for patients with relapsing multiple sclerosis who are 10 and older. The drug is now FDA approved for that population.
Biography
Dr. Chitnis is the Director of the Partners Pediatric MS Center at the Mass General Hospital for Children. She also sees adult patients with MS at the Brigham and Women's Hospital. She completed her medical training at the University of Toronto Medical School, her Neurology residency in Philadelphia, and a fellowship in Multiple Sclerosis and Neuroimmunology at the Brigham and Women's Hospital, Harvard Medical School. Dr. Chitnis has had a longstanding interest in Pediatric MS. She is the Chair of the International Pediatric MS Workgroup, and has written many publications and reviews related to multiple sclerosis. She is actively involved in several research projects to help to better understand and treat MS in children.
Neuroscience Care at Mass General
Through a combination of unmatched expertise, creativity and compassion, Mass General Neuroscience relentlessly advances the fields of Neurosurgery, Neurology and Psychiatry to unleash our patients’ potential.